15 February 2017 - The Department of Health has asked NICE to produce guidance on using venetoclax in the NHS in England for chronic lymphocytic leukaemia.

Venetoclax is not recommended within its marketing authorisation for treating chronic lymphocytic leukaemia in adults:

• who have a 17p deletion or TP53 mutation and who are unsuitable for, or whose disease has progressed after, a B-cell receptor pathway inhibitor or
  
• without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo-immunotherapy and a B-cell receptor pathway inhibitor.
  

Although the committee agreed that the end-of-life criteria were met, the ERG’s base-case ICERs were higher than the range usually considered to be a cost-effective use of NHS resources for end-of-life treatments.

The second appraisal committee meeting on 16 March 2017.

Read NICE Appraisal Consultation Document for venetoclax